Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.

We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.

Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.

ZERVIATE | Nicox

Product description

Nicox Valbonne, France

Price: N/A

Nicox
Valbonne, France